H. Lundbeck 배당금 및 환매

배당금 기준 확인 3/6

H. Lundbeck 수익으로 충분히 충당되는 현재 수익률 1.57% 보유한 배당금 지급 회사입니다.

주요 정보

1.6%

배당 수익률

0.1%

환매 수익률

총 주주 수익률	1.7%
미래 배당 수익률	2.8%
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	US$0.101
지급 비율	26%

최근 배당금 및 환매 업데이트

Recent updates

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 배당금 지급이 안정적인 반면, HLBB.F 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.

배당금 증가: HLBB.F 의 배당금 지급이 증가했지만 회사는 2 년 동안만 배당금을 지급했습니다.

시장 대비 배당 수익률

H. Lundbeck 시장 대비 배당 수익률

HLBB.F 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (HLBB.F)	1.6%
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Pharmaceuticals)	2.5%
애널리스트 예측 (HLBB.F) (최대 3년)	2.8%

주목할만한 배당금: HLBB.F 의 배당금( 1.57% )은 US 시장에서 배당금 지급자의 하위 25%( 1.39% )보다 높습니다. 1.39% ).

고배당: HLBB.F 의 배당금( 1.57% )은 US 시장에서 배당금 지급자의 상위 25% 4.32% ).

주주에 대한 수익 배당금

수익 보장: 합리적으로 낮은 지불 비율 ( 25.8% )로 HLBB.F 의 배당금 지급은 수익으로 충분히 충당됩니다.

주주에 대한 현금 배당금

현금 흐름 범위: 현금 지급 비율 ( 14.1% )이 낮기 때문에 HLBB.F 의 배당금 지급은 현금 흐름으로 완전히 충당됩니다.

H. Lundbeck 배당금 및 환매

배당금 기준 확인 3/6

주요 정보

최근 배당금 및 환매 업데이트

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Proposes Dividend for 2022

Recent updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금

강력한 배당금 지급 기업 알아보기